ISB News

ISB in Antarctica: Research Cruise Life

By Allison Lee

I just want to illustrate the work life out here. I have worked 20 straight days in a row. No weekends. No evenings off. Few breaks. Each day varies in time schedule but it usually consists of waking up at 7 a.m., taking at least two shots of espresso before working until lunch at 11:30 a.m. -12:30 p.m., working until dinner 5:30 p.m.-6:30 p.m. and working until 11 p.m., sometimes even until 2 a.m. It’s a good day when you can throw an hour in for an INSANITY work-out or a sauna break and get more than 7 hours of sleep. “Downtime” consists of uploading my Facebook photos, writing up blog drafts, organizing data, and reading textbooks on the Southern Ocean (all still work related). We all are starting to feel the strong desire for a weekend. And a beer. Just. One. Beer. On that note: Week three and we are out of fresh vegetables and fruits. It’s time for the canned goods, meat, carbs and cheese. I’m not complaining at all! I’m just sharing the reality of research life at sea. Only 38 more days to go! MISS YOU ALL XOXO

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.